{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:28:54Z","timestamp":1778117334911,"version":"3.51.4"},"reference-count":35,"publisher":"Royal College of General Practitioners","issue":"713","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Oral prednisolone is the mainstay treatment for bullous pemphigoid, an autoimmune blistering skin disorder affecting older people. Treatment with moderate-to-high doses is often initiated in secondary care, but then continued in primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To describe long-term oral prednisolone prescribing in UK primary care for adults with bullous pemphigoid from 1998 to 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>A prospective cohort study using routinely collected data from the Clinical Practice Research Datalink, a primary care database containing the healthcare records for over 17 million people in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Oral prednisolone exposure was characterised in terms of the proportion of individuals with incident bullous pemphigoid prescribed oral prednisolone following their diagnosis, and the duration and dose of prednisolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 2312 (69.6%) of 3322 people with bullous pemphigoid were prescribed oral prednisolone in primary care. The median duration of exposure was 10.6 months (interquartile range [IQR] 3.4\u201324.0). Of prednisolone users, 71.5% were continuously exposed for &gt;3 months, 39.7% for &gt;1 year, 14.7% for &gt;3 years, 5.0% for &gt;5 years, and 1.7% for &gt;10 years. The median cumulative dose was 2974 mg (IQR 1059\u20136456). Maximum daily doses were \u226510 mg\/day in 74.4% of prednisolone users, \u226520 mg\/day in 40.7%, \u226530 mg\/day in 18.2%, \u226540 mg\/day in 6.6%, \u226550 mg\/day in 3.8%, and \u226560 mg\/day in 1.9%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A high proportion of people with incident bullous pemphigoid are treated with oral prednisolone in UK primary care. Action is required by primary and second care services to encourage use of steroid-sparing alternatives and, where switching is not possible, ensure prophylactic treatments and proactive monitoring of potential side effects are in place.<\/jats:p><\/jats:sec>","DOI":"10.3399\/bjgp.2020.0870","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T13:35:16Z","timestamp":1629725716000},"page":"e904-e911","source":"Crossref","is-referenced-by-count":7,"title":["Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study"],"prefix":"10.3399","volume":"71","author":[{"given":"Monica SM","family":"Persson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E","family":"Harman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne R","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Vinogradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead M","family":"Langan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hippisley-Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1987","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"issue":"1","key":"2021112517301927000_71.713.e904.1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2021112517301927000_71.713.e904.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01190-w"},{"issue":"3","key":"2021112517301927000_71.713.e904.3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaad.2019.07.029","article-title":"Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients","volume":"82","author":"Narla","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2021112517301927000_71.713.e904.4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fmed.2020.00511","article-title":"The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study","volume":"7","author":"Kridin","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2021112517301927000_71.713.e904.5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2021112517301927000_71.713.e904.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04835.x"},{"key":"2021112517301927000_71.713.e904.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12072"},{"issue":"10079","key":"2021112517301927000_71.713.e904.8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2021112517301927000_71.713.e904.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592"},{"key":"2021112517301927000_71.713.e904.10","unstructured":"Joint Formulary Committee (2020) British National Formulary: prednisolone, https:\/\/bnf.nice.org.uk\/drug\/prednisolone.html (accessed 24 Sep 2021)."},{"issue":"4","key":"2021112517301927000_71.713.e904.11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00403-019-02010-y","article-title":"Association of pemphigus and pemphigoid with osteoporosis and pathological fractures","volume":"312","author":"Chovatiya","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"2021112517301927000_71.713.e904.12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.23736\/S0392-0488.17.05481-5","article-title":"Survey of bullous pemphigoid in an Italian university hospital: clinical-epidemiological characteristics and follow-up","volume":"153","author":"Balestri","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"issue":"10","key":"2021112517301927000_71.713.e904.13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/ijd.13736","article-title":"Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center","volume":"56","author":"Kremer","year":"2017","journal-title":"Int J Dermatol"},{"issue":"1","key":"2021112517301927000_71.713.e904.14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/ejd.2012.1906","article-title":"Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study","volume":"23","author":"Zhang","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2021112517301927000_71.713.e904.15","first-page":"335","article-title":"Bullous pemphigoid in Iranian patients: a descriptive study on 122 cases","volume":"50","author":"Esmaili","year":"2012","journal-title":"Acta Med Iran"},{"issue":"1","key":"2021112517301927000_71.713.e904.16","first-page":"66","article-title":"Prevalence and clinical features of Thai patients with bullous pemphigoid","volume":"29","author":"Kulthanan","year":"2011","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"8","key":"2021112517301927000_71.713.e904.17","first-page":"CR360","article-title":"Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000\u20132005","volume":"13","author":"Serwin","year":"2007","journal-title":"Med Sci Monit"},{"key":"2021112517301927000_71.713.e904.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.02040.x"},{"issue":"1","key":"2021112517301927000_71.713.e904.19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/jdds.jdds_1_18","article-title":"Bullous pemphigoid: profile and outcome in a series of 100 cases in Singapore","volume":"22","author":"Tan","year":"2018","journal-title":"J Dermatol Dermatol Surg"},{"issue":"2","key":"2021112517301927000_71.713.e904.20","first-page":"170","article-title":"Bullous pemphigoid seen at the National Skin Centre: a 2-year retrospective review","volume":"31","author":"Wong","year":"2002","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"2021112517301927000_71.713.e904.21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2230.1996.tb00005.x","article-title":"Bullous pemphigoid \u2014 a report of 86 cases from Taiwan","volume":"21","author":"Chang","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"2021112517301927000_71.713.e904.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23628.x"},{"key":"2021112517301927000_71.713.e904.23","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2021112517301927000_71.713.e904.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6732.1092"},{"key":"2021112517301927000_71.713.e904.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"2021112517301927000_71.713.e904.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"2021112517301927000_71.713.e904.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035934"},{"key":"2021112517301927000_71.713.e904.28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4440"},{"issue":"2","key":"2021112517301927000_71.713.e904.29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pds.4649","article-title":"Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data","volume":"28","author":"Joseph","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2021112517301927000_71.713.e904.30","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2589-7500(19)30012-3","article-title":"A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service","volume":"1","author":"Kuan","year":"2019","journal-title":"Lancet Digit Health"},{"key":"2021112517301927000_71.713.e904.31","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200108"},{"key":"2021112517301927000_71.713.e904.32","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.2.105"},{"issue":"3","key":"2021112517301927000_71.713.e904.33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ced.14086","article-title":"National audit on the management of bullous pemphigoid","volume":"45","author":"Smith","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2021112517301927000_71.713.e904.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01190-w"},{"key":"2021112517301927000_71.713.e904.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21984"}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2020.0870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T19:19:59Z","timestamp":1645816799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2020.0870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":35,"journal-issue":{"issue":"713","published-online":{"date-parts":[[2021,11,25]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.3399\/BJGP.2020.0870"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2020.0870","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}